

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Event overview:

The next big question in cancer immunotherapy is what's next in immune-oncology? Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

There have been remarkable advancements in cancer immunotherapy especially in the clinical development of immune checkpoint inhibitors, neoantigen-based immunotherapy and microbiome-derived immunotherapy in cancer. One of the most promising approach in terms of ACT (Adoptive Cell Transfer) is the CAR-T cell therapy which has recently received its second approval from the FDA.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiome-derived immunotherapy and new paradigms in immune checkpoint inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

Key Highlights:

- Neoantigens in personalized Cancer Immunotherapy
- Immune Checkpoint Inhibitors and Combinations (PD-1, PD-L1, PD-L4)
- Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
- Neoantigen Discovery by Next-Generation Sequencing
- Biomarkers and Cancer Vaccines
- CAR-T cell therapy, Dendritic Cell Therapy
- Microbiome in Cancer Immunotherapy (Targets and Challenges)
- Oncolytic viruses
- Tumor associated Macrophages as treatment in IO
- Technologies for personalized TCR engineered cancer immunotherapies
- Tumor microenvironment

Who Should Attend?

From Pharmaceutical, Biopharmaceutical, Biotechnology, Hospitals and Research Institutes:

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group leaders, Clinicians, Professor, Assistant professors, Research fellow, PhD working on

Neoantigens and Microbiome	Cellular Therapy	Immune Checkpoint Inhibitors
• Neoantigen-based therapies • Tumour antigens • Tumour immunotherapy • Neoepitopes • Cancer Vaccines • Cancer biomarkers • Tumour microenvironment • Clinical microbiology • Immunology • Microbiome/microbial genomics • Preclinical and Translational IO	• Cell-Based Immunotherapies • Innate and adaptive immune cells • Tumour antigens and neoantigens • Cell and gene therapy • CAR-T cell therapy • T-cell receptors • Heamatology	• Cancer immunotherapy • Immune checkpoint targets • Checkpoint inhibition • Cellular therapy • Clinical research • Combination therapy • Cancer Vaccines • Preclinical and Translational Oncology R&D • Immune biomarkers • Immunology • Cancer biology • Immuno-oncology • Tumour-associated mechanisms of immune suppression



MARKETSANDMARKETS

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Gold Sponsor:

Lonza

Silver Sponsors:

MITRABIOTECH 



A^{CD}
a biotechne brand

Exhibitors & Sponsors:



in *sphero*

NEBION

MBL[®]
International Corporation

 MEDGENOME

 CARIS[®]
LIFE SCIENCES

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Advisory Panel:



Stefan Gluck

Vice President, Global Medical Affairs, Solid Tumors, Immuno-Oncology and Early Assets, Celgene, USA



Roy Baynes

Senior Vice President, Chief Medical Officer, Head of Global Clinical Development Merck Research Laboratories, USA



John Delaney

Head, Translational Medicine and Bioinformatics Agenus, USA

Speaker Panel:



Stefan Gluck

Vice President, Global Medical Affairs, Solid Tumors, Immuno-Oncology and Early Assets, Celgene, USA



Robert Iannone

Senior Vice President, Head, Immuno-Oncology AstraZeneca, USA



Eugene Zhukovsky

Chief Scientific Officer Biomunex Pharmaceuticals, France



Roy Baynes

Senior Vice President, Chief Medical Officer, Head of Global Clinical Development Merck Research Laboratories, USA



Stephen Schoenberger

Professor of Immunology La Jolla Institute for Allergy and Immunology, USA



Ildiko Csiki

Vice President, Clinical Development Immuno-Oncology Inovio, USA



Laura Johnson

Senior Director, Head Translational Medicine, Oncology Cell Therapy GSK, USA



Rakesh Dixit

Vice President, R&D MedImmune, USA



John Delaney

Executive Director, Research Amgen, USA



Andrew Allen

CEO Gritstone Oncology, USA



Ezio Bonvini

Senior Vice President, CSO MacroGenics, USA



Pranab Mukherjee

Associate Professor Case Western Reserve University, USA



Steve Doberstein

Senior Vice President, CSO Nektar Therapeutics, USA



Pramod Srivastava

Director of the Carole and Ray Neag Comprehensive Cancer Center University of Connecticut, USA




Julia Oh

Assistant Professor The Jackson Laboratory, USA



Daniel Levey

Senior Director Vaccine Research Agenus, USA



Liang Deng

Physician-Scientist, Dermatologist Memorial Sloan Kettering Cancer Centre, USA



Natalie Russi

Scientific Project Manager Nebion, Sweden



Shahram Salek-Ardakani

Director, Cancer Immunology Pfizer, USA



Tony Polverino

Chief Scientific Officer Kite Pharma, USA



Terry Fisher

Director, Translational Science and Bioanalytical Vaccinex, USA



Aiman Shalabi

Chief Medical Officer Cancer Research Institute, USA



Daniel Powell

Associate Professor of Pathology and Laboratory Medicine University of Pennsylvania, USA



Ellen Pure

Professor and Chair, Department of Biomedical Sciences University of Pennsylvania, USA



Carl Morrison

Executive Director of the Center for Personalized Medicine Roswell Park Cancer Institute, USA



Daniel O'Connor

CEO OncoSec, USA



Jessica Flechtner

Chief Scientific Officer Genocoea, USA



John Castle

Head, Translational Medicine and Bioinformatics Agenus, USA

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Speaker Panel:



Joost Oppenheim

Head, Cellular Immunology Section
NIH, USA



Eytan Barnea

Founder and Chief Scientist
BioIncept LLC, USA



Lata Jayaraman

Head, Tumor Immunotherapy
Seres Therapeutics



Papia Chakraborty

Senior Scientist, Head, Immuno-Oncology
Medgenome, USA



Sr. Representative

Insphero, USA



Christophe Queva

Chief Scientific Officer
Oncorus, USA



Patrick Hanley

Director, GMP for Immunotherapy, Assistant
Professor
Children's National Medical Centre, USA



Gregory Alberts

Global Subject Matter Expert
Lonza Pharma Bioscience Solutions



Pirouz Daftarian

Application Manager, IO/Vaccines
MBL International /JSR Micro, Life Sciences Inc.



Sr. Representative

ACD-Bio-Biotechnie



Roderick O'Connor

Senior Research Investigator
University of Pennsylvania, USA



Frank Walsh

CEO
Ossianix Inc.



Mark Paris,

Associate Director, Translational
Applications,
Mitra Biotech, USA



Raj Chavali

Senior Director
Caris Lifesciences, USA



Nick Sarlis

Chief Medical Officer & Senior VP
Sellas Life Sciences, USA



Ashok Shrivastava

CEO
Cure Pharmaceuticals, USA



Mithun Khattar

Immuno-Oncology Lead
Takeda Oncology, USA



Holly Koblish

Director, Pharmacology
Incyte, USA



Leeladhar Sammatur

Vice President, Product development &
Manufacturing, Immunovaccine, USA



MARKETSANDMARKETS

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Day 1 - June 21st 2018

Cellular Therapy & Neoantigens	Immune Checkpoint Inhibitors & Combination Therapies
09:00 Opening remarks from the Chairman	09:00 Opening remarks from the Chairman
09:05 Keynote: Arming NY-ESO-1-Specific TCR-T Cells to Overcome the Suppressive Tumor Microenvironment	09:05 Keynote: PD-1 Antibody is transforming cancer treatment both as a monotherapy and in combination • Biologically informed analysis of big data sets enabled initial identification of PD-1 antibody responsive cancers • Monotherapy activity has established benefit and is been further explored across a broad array of cancers • Informative biology helps identify patients for whom monotherapy is appropriate and those for whom additional therapeutic options should be explored • Precision medicine helps define potential mechanisms of primary and secondary treatment resistance as well as rational selection of combination strategies Roy Baynes , Senior Vice President, Chief Medical Officer, Head of Global Clinical Development, Merck Research Laboratories, USA
09:35 Identifying tumor neoantigens in silico with confidence – applying artificial intelligence • Tumor neoantigens are infrequent – a small subset of all tumor mutations • Accurate prediction of tumor neoantigens is critical for targeted immunotherapy • Training an artificial intelligence-based model with large amounts of human tumor surface-presented HLA-peptide data enabled development of a tumor neoantigen prediction model that delivers a breakthrough in predictive accuracy Andrew Allen , CEO, Gritstone Oncology, USA	09:35 Curative anti-tumor vaccine consisting of a TLR4 ligand (HMGN1), TLR7/8 ligand (R848) and a checkpoint inhibitor • This regimen cures 5 of 7 large (1 cm. Diam.) mouse tumors of the colon , liver, thymoma, kidney or lung • The cured mice exhibit long term specific immunity to the cured tumors Joost Oppenheim , Head, Cellular Immunology Section, NIH, USA
10:05 The Lonza Nucleofector™ platform is superb at the delivery of CRISPR RNP, and can facilitate Immunotherapy research and therapies • Nucleofection is known for the ability to transfect human T cells, CD34+ cells, MSCs, and iPSCs. • The LV Nucleofector™ can transfect up to 2 billion cells in a closed system, ideal for autologous gene therapies, and is being included in Phase 1 Clinical Trials. Gregory Alberts , Global Subject Matter Expert, Lonza Pharma Bioscience Solutions	10:05 Solution Provider Presentation -Please contact sanjib.biswas@marketsandmarkets.com
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings	
Therapeutic approach in Cell Therapy & Neoantigens	Pre-clinical & Translational Immuno-Oncology Developments
11:25 Solution Provider Presentation-Please contact sanjib.biswas@marketsandmarkets.com	11:25 Translational Considerations for Development of Immune Checkpoint Agonists/Antagonists and Their Combinations • Preclinical challenges to development of immune-oncology (IO) gents • Prediction of safety of individual and combinations of IO agents • Translational medicine approaches to combination IO development Rakesh Dixit , Vice President, R&D, MedImmune, USA
11:55 DepoVax™ - An effective lipid-based vaccine delivery system which produces a rapid, robust and sustained immune responses against diverse targets • The use of synthetic peptides, recombinant proteins and nucleic acids in the development of prophylactic and therapeutic vaccines has expanded. However, the success rate of these vaccines can be limited by the poor solubility and stability of antigens during manufacturing and storage. • DepoVax™ is an amphipathic lipid-based formulation that delivers combined antigen(s)/adjuvant targets in a water-free oil diluent formulation. At the site of injection, DepoVax creates a unique depot by retaining all components within the oil diluent. This forces an active uptake and trafficking of antigen by antigen presenting cells which in turn elicits a strong, sustained and specific immune response against target antigens. • In my talk I will present a brief manufacturing method and characterization of several unique vaccine candidates formulated in DepoVax, especially, peptide based antigens including a single peptide-based RSV vaccine (DPX-RSV) for infectious disease indication and multiple peptides (14-35 Neoantigens) for Personalized cancer formulations (DPX-NEO) with correlations to immunogenicity data. Leeladhar Sammat , Vice President, Product development & Manufacturing, Immunovaccine, USA	11:55 Preclinical and Translational Immuno-Oncology Developments Ezio Bonvini , Senior Vice President, CSO, MacroGenics, USA

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

12:25 Agenus' Synthetic Neoantigen Vaccine Platforms, Including Novel Phosphopeptide Tumor Targets Daniel Levey , Senior Director Vaccine Research, Agenus, USA		12:25 Combined Inhibition of IDO1 and Checkpoint Modulators as an Effective Therapeutic Strategy in Cancer • IDO1 as a tumor-resistance mechanism – preclinical data • The IDO1 inhibitor, epacadostat – PK/PD preclinical and clinical • Emerging clinical data in combination with PD1/PDL1 axis blockade Holly Koblisch , Director, Incyte, USA
12:55 Lunch and Poster Presentations One-to-One Networking Meetings		
Neoantigens	Immune Checkpoint Inhibitors and Combination Therapies	Cellular Therapy
Neoantigen-based Biomarkers and Cancer Vaccines	New Immune Checkpoints for Immunotherapy	Developments in CAR-T cell therapy
13:55 Predicting good cancer neoepitopes: the consensus and the evidence • The neoepitopes that elicit immunity must have a strong binding affinity to the MHC or the HLA alleles • Neoepitopes identified by CD8 cells are likely to be good neoepitopes; conversely, neoepitopes which are not recognized by CD8 cells by current assays, are not worthwhile • These issues will be discussed in light of new data from mouse & human tumors Pramod Srivastava , Director of the Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut, USA	13:55 PIVOTing Tumors from Cold to Hot: NKTR-214 and anti-PD1 Combination Therapies • NKTR-214 is an engineered cytokine that is a biased agonist of CD122 • Combination therapy with anti-PD1 antibodies and NKTR-214 increases TILs and strengthens PD-L1 expression in PD-L1 negative tumors • The combination of NKTR-214 and anti-PD-1 antibodies are very well tolerated, with a very low rate of mild immunological AEs Steve Doberstein , Senior Vice President, CSO, Nektar Therapeutics, USA	13:55 Heterogeneity of cancer associated fibroblasts in solid tumors • Targeting pro-tumorigenic stromal cells using chimeric antigen receptor (CAR) T cells • Stroma-dependent molecular pathways that promote primary tumor growth and metastasis of solid tumors Ellen Pure , Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania, USA
14:35 ATLAS™ - Challenging Current Dogma through Neoantigen Identification and Characterization using Patient T cells • ATLAS™ is a clinically-proven platform that can comprehensively characterize the specificity and quality of HLA-diverse human T cell responses • T cell neoantigens identified using ATLAS are often missed by algorithms • Inhibitory neoantigens are emerging that could not be predicted in silico Jessica Flechtner , Chief Scientific Officer, Genocea, USA	14:35 Solution Provider Presentation	14:35 Tumor intrinsic and extrinsic factors determining drug efficacy and long-term survival • NGS based identification of immune cell content of tumors • Identifying immunogenic features of prognosis in human cancers Papia Chakraborty , Senior Scientist, Head, Immuno-Oncology, Medgenome, USA
15:05 Unbiased Functional Identification of Personalized Neoantigens • Development of a novel genomic sequencing/bioinformatics/functional immunology approach • Comparison with purely computational neoantigen identification methods • Superior identification of patient-specific neoantigens for immunotherapeutic targeting Stephen Schoenberger , Professor of Immunology, La Jolla Institute for Allergy and Immunology, USA	15:05 Panel Discussion: Are we doing the right thing by doing so many combinations together?	15:05 Panel Discussion: Will CAR-T cells successfully expand into tumors that are not T-cell tumors?



MARKETSANDMARKETS

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

15:35 Preimplantation Factor (PIF) Potential in Immuno Oncology Treatment - PIF completed Phase I clinical trial demonstrating safety - PIF protects against radiation and sensitizes human tumors to radiation (murine) - PIF differentiates human glioma metastatic cells to lose tumorigenicity - PIF reduces metastatic melanoma by increasing tumor footprint and autophagy Eytan Barnea, Founder and Chief Scientist, BioIncept LLC, USA	15:35 IO Combinations with Semaphorin 4D Antibody Facilitate Immune Infiltration and Shift the Immune Balance in the Tumor Microenvironment - Semaphorin 4D (SEMA4D) creates a barrier at the invasive tumor margin to restrict immune cell infiltration and promotes immunosuppressive activity of myeloid cells - In preclinical studies, antibody blockade of SEMA4D can reverse these effects to stimulate immune-mediated tumor killing and enhance activity of other immunotherapies. This represents a novel approach to target the interaction between tumor and stroma - In clinical trials, VX15/2503, a humanized IgG4 antibody to SEMA4D, will be evaluated in combination with immune checkpoint inhibitors in patients with solid tumors, as well as evaluation of single agent VX15 in pediatric oncology and osteosarcoma Terry Fisher, Director, Translational Science and Bioanalytical Vaccinex, USA	15:35 Therapeutic levels of antibodies can be delivered to the CNS via a VNAR transferrin receptor shuttle for Neuro Oncology applications - Use of single domain VNAR antibody platform to develop BBB shuttles targeting the Transferrin Receptor - Delivery of therapeutic antibodies to CNS as assessed by ELISA, histology, 2-photon imaging and functional POC studies - Development of BBB penetrant bispecific antibodies to rituximab for CNS lymphoma and PD-L1 and Egfr antibodies for glioblastoma - Ossianix has developed a robust BBB shuttle that opens a way to deliver therapeutic levels of antibodies for many Neuro Oncology indications Frank Walsh, CEO, Ossianix Inc.
16:05 Evening Refreshments and Poster Presentations One-to-One Networking Meetings		
16:55 Targeting tumor neoantigens - Neoantigens are ideal targets - HLA peptide presentation is a step to identify neoantigens - Clinical trials, including combinations, demonstrate response John Castle, Head, Translational Medicine and Bioinformatics, Agenus, USA	16:55 Breast cancer and immunotherapy Ashok Shrivastava, CEO, Cure Pharmaceuticals, USA	16:55 Overcoming Challenges in the Cellular Therapy Laboratory – an Academic Perspective - How we are using cellular therapies to improve outcomes after BMT - How we are leveraging this knowledge to move beyond BMT - What challenges we face as an academic center and how we are working to overcome them Patrick Hanley, Director, GMP for Immunotherapy, Assistant Professor, Children's National Medical Centre, USA
17:25 Cancer Vaccination as a Therapeutic Application of Tumor Neoantigen Profiling	17:25 A Tale of Two Cancer Vaccines: Into the Foray of Combination Therapies Targeting WT1 and HER2 - Galinpepimut-S (GPS): Potential efficacy 'signals' in several tumor types: Is WT1 immune targeting with heteroclitic peptides coming of age? - GPS plus Checkpoint Inhibitors: why a combination could work and what studies are being done/planned? - Nelipepimut-S (NeuVax) plus Trastuzumab in TNBC: Anti-HER2 Vaccination Redux? Nick Sarlis, Chief Medical Officer & Senior VP, Sellas Life Sciences, USA	17:25 Dendritic Cell Therapy in IO
17:55 Closing remarks from the Chairman	17:55 Closing remarks from the Chairman	17:55 Closing remarks from the Chairman

Media Partners:



Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Day 2 - June 22nd 2018

Microbiome	Immune Checkpoint Inhibitors and Combination Therapies	Cellular Therapy
Microbiome in Cancer Immunotherapy	Personalized Immunotherapy and Viral Therapies	Technologies for Personalized T Cell Receptor Engineered Cancer Immunotherapies
09:00 Opening remarks from the Chairman	09:00 Opening remarks from the Chairman	09:00 Opening remarks from the Chairman
09:05 Keynote: Leveraging gut microbiota networks to impact tumor immunotherapy • The concept of “reverse translation” as a strategy for microbiome drug discovery - Identification of a microbiome signature and its association with treatment and response • Use of metagenomics and metabolomics to deconvolute functional fingerprints of complex ecology to identify specific species and strains • Integration of computational strategies with empirical phenotyping and screening to drive drug design • Designing compositions of microorganisms that form “functional ecological networks” and can impact response to therapy Lata Jayaraman, Head, Tumor Immunotherapy, Seres Therapeutics	09:05 Keynote: Improving efficacy of CPI's by selected combination therapy Shahram Salek-Ardakani, Director, Cancer Immunology, Pfizer, USA	09:05 Keynote: Pivotal trial of Axi-cel in patients with refractory aggressive NHL • Long-term follow up of Zuma-1 • Improving the safety profile of Axi-cel • Combination with check point inhibitors Tony Polverino, Chief Scientific Officer, Kite Pharma, USA
09:35 Role of Mycobiome-Bacteriome interactions in Cancer • Dysbiosis in Bacterial and Fungal Microbiomes • Inter-kingdom correlations in microbiome • Immune and host correlates with microbial dysbiosis Pranab Mukherjee, Associate Professor, Case Western Reserve University, USA	09:35 “Why don't we have positive studies in pancreatic cancer with IO compounds?” • Pancreatic cancer has not been one of the Successful diseases for immuno therapy • It is regarded as immunologically “cold” tumor • Some new data indicate it might be susceptible to ICI in combination with Chemotherapy and other IO agents • New concepts and data will be discussed Stefan Gluck, Vice President, Global Medical Affairs, Solid Tumors, Immuno-Oncology and Early Assets, Celgene, USA	09:35 Pre-clinical modeling of immune responses to cancer: from bench-side to clinical outcomes: • Fundamental differences in immune composition, tumor microenvironments and disease progression between mice and humans. • Preclinical models in immune-oncology: what translates and what doesn't. • How to leverage the data from pre-clinical studies and minimize translational failures. Mithun Khattar, Immuno-Oncology Lead, Takeda Oncology, USA
10:05 Solution Provider Presentation	10:05 Transforming Translational Research: CANscript™ - A Better Predictive Model for Oncology • Ex vivo, human tumor culture recreation the TME using fresh tumor tissue, autologous plasma and PBMCs • Validated to predict clinical response based on performance across >2,000 patients • Used to assess MOA, indication scout and compare response across multiple arms of interrogation • Prioritize candidate compounds, reposition approved therapeutics, de-risk programs Mark Paris, Associate Director, Translational Applications, Mitra Biotech, USA	10:05 Solution Provider Presentation
10:35 Morning Refreshments and Poster Presentations One-to-One Networking Meetings		

Next Gen

Immuno-Oncology Congress

June 21st - 22nd 2018, Radisson Hotel Philadelphia Northeast, Philadelphia-USA

Microbiome	Immune Checkpoint Inhibitors and Combination Therapies	Cellular Therapy
11:25 Models of Microbial Adjuvants and Biomarkers of Cancer Immunotherapy • The microbiome is a likely modulator and predictor of immunotherapy response • We have developed an experimental platform to identify probiotic candidates using humanized mice • Our goals are to systematically characterize the ability of the gut microbiome to improve immunotherapy outcomes in cancer and how this differs between different individuals Julia Oh , Assistant Professor, The Jackson Laboratory, USA	11:25 The rationale of combination of viral-based cancer immunotherapy with immune checkpoint blockade • Current status of oncolytic virotherapy • Evolving concepts of oncolytic virotherapy • Two platforms of vaccinia-based cancer immunotherapy she and her colleagues developed at MSKCC- recombinant MVA-based expressing immunoactivators and oncolytic vaccinia expressing immune checkpoint blockade antibody Liang Deng , Physician-Scientist, Dermatologist, Memorial Sloan Kettering Cancer Centre, USA	11:25 Hypoxia-induced reactive oxygen species contribute to immune checkpoint molecule expression in T cells undergoing rapid clonal proliferation • Etomoxir-induced oxidative stress induces the expression of immune checkpoint molecules PD-1, Tim-3, and Lag-3 • The immune checkpoint molecule Tim-3, is upregulated by T cells in highly hypoxic xenograft tumors independent of TCR activation • The induction of immune checkpoint molecules is calcineurin-dependent and reversed by the antioxidant N-acetyl cysteine • Immune checkpoint molecules are part of a natural regulatory system (ROS sensitive) to temper activation and limit oxidative damage to T cell clones necessary for long-lasting immunity Roderick O’Connor , Sr. Research Investigator, University of Pennsylvania, USA
11:55 Targets and Challenges of Microbiome during Immunotherapy	11:55 Targeted Oncolytic Viro-immunotherapy for the Treatment of Brain Tumor • Oncorus developed a new class of miR attenuated oncolytic vectors that selectively infect and replicate in cancer cells • Oncorus vectors are armed with multiple payloads to improve vector delivery, replication, spread and to induce a tumor-specific immune response • The preclinical development of Oncorus first clinical candidate for the treatment of glioblastoma multiforme will be presented. Christophe Queva , Chief Scientific Officer, Oncorus, USA	11:55 Comprehensive Analysis of the Immuno-Oncology Landscape • Summary of all IO agents in clinical and pre-clinical development • Summary of IO targets in clinical development • Summary of all PD-1 combination trials in development • Proposed solutions for efficiencies Aiman Shalabi , Chief Medical Officer, Cancer Research Institute, USA
12:25 Strategies in regulating the microbiome in translational IO	12:25 Functional screening of immune checkpoint inhibitors (ICIs) using a pool of MHC tetramers made with the QuickSwitch™ peptide exchange platform • A potency assay for ICB also predicts unresponsiveness to ICI • Immune monitoring •Peptide exchange MHC tetramer platform (no UV) Pirouz Daftarian , Application Manager, IO/Vaccines, MBL International /JSR Micro, Life Sciences Inc.	12:25 ASPIRE platform for cancer immunotherapy Covering the Aspire platform; studies in head and neck cancer; prostate cancer and additional combination studies Ildiko Csiki , Vice President, Clinical Development Immuno-Oncology, Inovio, USA
12:55 Lunch and Poster Presentations One-to-One Networking Meetings		
Cellular Therapy & Neoantigens		Immune Checkpoint Inhibitors & Combination Therapies
13:55 Comparing immunological marker signatures across various cancer types • Analyze immune-cell induced gene expression patterns in cancer tissues • Globally normalized public data sets provide novel insights to drug response patterns Natalie Russi , Scientific Project Manager, Nebion, Sweden	13:55 Role of Nanotechnology with a combinatorial approach for solid tumors	
14:25 Caris’ Integrated biomarker and predictive test strategies in Oncology • Caris’ tumor profiling strategies and integrated PanOmic approach for biomarkers in personalized medicine • Patient referral and identifying the right patients for the trials • MSI analysis using NGS platform and interesting correlation between MSI, PD-L1, and TMB (recent Science publication using Caris technologies) • Novel and disruptive Target ID and Predictive Test technology – Multiplex Aptamer based approach to enrich the biomarker strategies Raj Chavali , Senior Director, Caris Lifesciences, USA	14:25 Solution Provider Presentation	
14:55 Neoantigens and beyond: Future developments	14:55 Future opportunities in clinical development of ICI combinations	
15:25 Closing remarks from the Chairman	15:25 Closing remarks from the Chairman	
15:30 End of Conference		